Overview

Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects

Status:
Completed

Trial end date:
2010-04-26

Target enrollment:

Participant gender:

Summary

The purpose of this study is to see if the Pharmacokinetics and the Safety Profile of GSK573719 and GSK573719/GW642444 are effected by concurrent dosing with the PGP inhibitor verapamil.

Phase:

Phase 1

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Verapamil